van Dongen GA - Search Results

1

Development and characterization of clinical-grade 89Zr-trastuzumab for HER2/neu immunoPET imaging.

Dijkers EC, Kosterink JG, Rademaker AP, Perk LR, van Dongen GA, Bart J, de Jong JR, de Vries EG, Lub-de Hooge MN. Dijkers EC, et al. Among authors: van dongen ga. J Nucl Med. 2009 Jun;50(6):974-81. doi: 10.2967/jnumed.108.060392. Epub 2009 May 14. J Nucl Med. 2009. PMID: 19443585 Free article.

2

Phase I therapy study of 186Re-labeled chimeric monoclonal antibody U36 in patients with squamous cell carcinoma of the head and neck.

Colnot DR, Quak JJ, Roos JC, van Lingen A, Wilhelm AJ, van Kamp GJ, Huijgens PC, Snow GB, van Dongen GA. Colnot DR, et al. Among authors: van kamp gj, van dongen ga, van lingen a. J Nucl Med. 2000 Dec;41(12):1999-2010. J Nucl Med. 2000. PMID: 11138685 Free article. Clinical Trial.

3

Optimal quality (131)I-monoclonal antibodies on high-dose labeling in a large reaction volume and temporarily coating the antibody with IODO-GEN.

Visser GW, Klok RP, Gebbinck JW, ter Linden T, van Dongen GA, Molthoff CF. Visser GW, et al. Among authors: van dongen ga. J Nucl Med. 2001 Mar;42(3):509-19. J Nucl Med. 2001. PMID: 11337531 Free article.

4

89Zr immuno-PET: comprehensive procedures for the production of 89Zr-labeled monoclonal antibodies.

Verel I, Visser GW, Boellaard R, Stigter-van Walsum M, Snow GB, van Dongen GA. Verel I, et al. Among authors: van dongen ga. J Nucl Med. 2003 Aug;44(8):1271-81. J Nucl Med. 2003. PMID: 12902418 Free article.

5

Quantitative 89Zr immuno-PET for in vivo scouting of 90Y-labeled monoclonal antibodies in xenograft-bearing nude mice.

Verel I, Visser GW, Boellaard R, Boerman OC, van Eerd J, Snow GB, Lammertsma AA, van Dongen GA. Verel I, et al. Among authors: van eerd j, van dongen ga. J Nucl Med. 2003 Oct;44(10):1663-70. J Nucl Med. 2003. PMID: 14530484 Free article.

6

Dosimetric analysis of radioimmunotherapy with 186Re-labeled bivatuzumab in patients with head and neck cancer.

Postema EJ, Börjesson PK, Buijs WC, Roos JC, Marres HA, Boerman OC, de Bree R, Lang M, Munzert G, van Dongen GA, Oyen WJ. Postema EJ, et al. Among authors: van dongen ga. J Nucl Med. 2003 Oct;44(10):1690-9. J Nucl Med. 2003. PMID: 14530488 Free article. Clinical Trial.

7

High-quality 124I-labelled monoclonal antibodies for use as PET scouting agents prior to 131I-radioimmunotherapy.

Verel I, Visser GW, Vosjan MJ, Finn R, Boellaard R, van Dongen GA. Verel I, et al. Among authors: van dongen ga. Eur J Nucl Med Mol Imaging. 2004 Dec;31(12):1645-52. doi: 10.1007/s00259-004-1632-8. Epub 2004 Jul 31. Eur J Nucl Med Mol Imaging. 2004. PMID: 15290121

8

The promise of immuno-PET in radioimmunotherapy.

Verel I, Visser GW, van Dongen GA. Verel I, et al. Among authors: van dongen ga. J Nucl Med. 2005 Jan;46 Suppl 1:164S-71S. J Nucl Med. 2005. PMID: 15653665 Free article. Review.

9

(89)Zr as a PET surrogate radioisotope for scouting biodistribution of the therapeutic radiometals (90)Y and (177)Lu in tumor-bearing nude mice after coupling to the internalizing antibody cetuximab.

Perk LR, Visser GW, Vosjan MJ, Stigter-van Walsum M, Tijink BM, Leemans CR, van Dongen GA. Perk LR, et al. Among authors: van dongen ga. J Nucl Med. 2005 Nov;46(11):1898-906. J Nucl Med. 2005. PMID: 16269605 Free article.

10

Radioimmunotherapy of head and neck cancer xenografts using 131I-labeled antibody L19-SIP for selective targeting of tumor vasculature.

Tijink BM, Neri D, Leemans CR, Budde M, Dinkelborg LM, Stigter-van Walsum M, Zardi L, van Dongen GA. Tijink BM, et al. Among authors: van dongen ga. J Nucl Med. 2006 Jul;47(7):1127-35. J Nucl Med. 2006. PMID: 16818947 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

240 results

Search Page

Filters